MOG and primary progressive multiple sclerosis: Compound 12 (Figure 8) was shown to be also able to reduce myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (MOG-EAE) disease progression, severity, and neuropathological markers by (i) promoting neurosteroid allopregnenolone synthesis in the CNS and (ii) increasing the production of anti-inflammatory IL-10, evidencing its potential use as a tool against primary progressive multiple sclerosis (PPMS) or severe multiple sclerosis (MS) [60].